Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers

NCT ID NCT06390995

Ongoing Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has two parts: the first checks safety and the right dose, and the second looks at how well it controls the cancer. About 28 participants will receive the drug every three weeks for up to 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
mirvetuximab soravtansine (a drug that targets a protein called folate receptor alpha on cancer cells and delivers a toxin to kill them)
What this could lead to
If successful, this could provide a new treatment option for Japanese patients with advanced ovarian cancer and other solid tumors that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 28 participants, so results may not apply to a larger population. Side effects, including eye problems, lung inflammation, and nerve damage, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma colorectal cancer endometrial cancer gastroesophageal adenocarcinoma neoplasm non-small cell lung carcinoma ovarian cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER SOLID TUMORS

Contacts and locations

Locations

  • Aichi Cancer Center

    Nagoya, Aichi-ken, Japan

  • Cancer Institute Hospital of JFCR

    Koto-ku, Tokyo, Japan

  • Chiba University Hospital

    Chiba, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • Hyogo Cancer Center

    Akashi, Hyōgo, Japan

  • Iwate Medical University Hospital

    Shiwa-gun, Iwate, Japan

  • Jikei University Kashiwa Hospital

    Kashiwa, Chiba, Japan

  • Keio University Hospital

    Shinjuku-ku, Tokyo, Japan

  • Kurume University Hospital

    Kurume, Fukuoka, Japan

  • Kyoto University Hospital

    Kyoto, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan

  • Okayama University Hospital

    Okayama, Japan

  • Osaka International Cancer Institute

    Osaka, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan

  • Sapporo Medical University Hospital

    Sapporo, Hokkaido, Japan

  • Shikoku Cancer Center

    Matsuyama, Ehime, Japan

  • Shizuoka Cancer Center

    Nakatogari, Shizuoka, Japan

  • The Jikei University Hospital

    Minato-ku, Tokyo, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.